Your browser doesn't support javascript.
loading
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.
Temesgen, Zelalem; Assi, Mariam; Shweta, F N U; Vergidis, Paschalis; Rizza, Stacey A; Bauer, Philippe R; Pickering, Brian W; Razonable, Raymund R; Libertin, Claudia R; Burger, Charles D; Orenstein, Robert; Vargas, Hugo E; Palraj, Raj; Dababneh, Ala S; Chappell, Gabrielle; Chappell, Dale; Ahmed, Omar; Sakemura, Reona; Durrant, Cameron; Kenderian, Saad S; Badley, Andrew D.
Afiliação
  • Temesgen Z; Division of Infectious Diseases, Mayo Clinic, Rochester, MN. Electronic address: Temesgen.zelalem@mayo.edu.
  • Assi M; Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
  • Shweta FNU; Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
  • Vergidis P; Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
  • Rizza SA; Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
  • Bauer PR; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
  • Pickering BW; Department of Anesthesia and Critical Care Medicine, Mayo Clinic, Rochester, MN.
  • Razonable RR; Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
  • Libertin CR; Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL.
  • Burger CD; Division of Pulmonary Medicine, Mayo Clinic, Jacksonville, FL.
  • Orenstein R; Division of Infectious Diseases, Mayo Clinic, Scottsdale, AZ.
  • Vargas HE; Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ.
  • Palraj R; Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
  • Dababneh AS; Division of Infectious Diseases, Mayo Clinic, Rochester, MN.
  • Chappell G; Humanigen, Inc, Burlingame, CA.
  • Chappell D; Humanigen, Inc, Burlingame, CA.
  • Ahmed O; Humanigen, Inc, Burlingame, CA.
  • Sakemura R; T Cell Engineering, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Durrant C; Humanigen, Inc, Burlingame, CA.
  • Kenderian SS; T Cell Engineering, Mayo Clinic, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN; Department of Immunology, Mayo Clinic, Rochester, MN; Department of Molecular Medicine, Mayo Clinic, Rochester, MN.
  • Badley AD; Division of Infectious Diseases, Mayo Clinic, Rochester, MN; Department of Molecular Medicine, Mayo Clinic, Rochester, MN.
Mayo Clin Proc ; 95(11): 2382-2394, 2020 11.
Article em En | MEDLINE | ID: mdl-33153629
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator Estimulador de Colônias de Granulócitos e Macrófagos / Anticorpos Monoclonais Humanizados / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mayo Clin Proc Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator Estimulador de Colônias de Granulócitos e Macrófagos / Anticorpos Monoclonais Humanizados / SARS-CoV-2 / Tratamento Farmacológico da COVID-19 Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mayo Clin Proc Ano de publicação: 2020 Tipo de documento: Article